A Phase 2, Open-label, Multicenter, Dose-Escalation and Expansion Study of Venetoclax in Combination with Pomalidomide and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Administered By

Awarded By

Contributors

Start/End

  • October 25, 2018 - October 31, 2023